Abstract #0476
Hyperpolarized [1- 13 C] glutamate: a surrogate marker of IDH1 mutational status in glioblastoma
Myriam M Chaumeil 1 , Peder E.Z. Larson 1 , Sarah M Woods 1 , Pia Eriksson 1 , Larry Cai 1 , Aaron Robinson 2 , Daniel B Vigneron 1 , Sarah J Nelson 1 , Russell O Pieper 2 , Joanna J Phillips 2 , and Sabrina M Ronen 1,2
1
Radiology and Biomedical Imaging, UCSF, San
Francisco, CA, United States,
2
Brain
Tumor Research Center, UCSF, San Francisco, CA, United
States
Following injection of hyperpolarized α-ketoglutarate,
we previously reported the detection of hyperpolarized
2-hydroxyglutarate formation in IDH1-mutant tumors, not
in in IDH1 wild-type, using 2D
13
C
dynamic CSI at clinical field strength. Here, we show
that, contrarily to 2-hydroxyglutarate, hyperpolarized
glutamate formation from hyperpolarized α-ketoglutarate
could be detected in IDH1 wild-type perfused cells and
tumors only, not in cells or tumors harboring the IDH1
mutation. Biochemical assays were performed to assess
the underlying mechanisms. Hyperpolarized glutamate
could thus potentially serve as a non-invasive
additional surrogate marker of IDH1 mutational status in
brain tumors.
This abstract and the presentation materials are available to members only;
a login is required.
Join Here
